FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2961756674> ?p ?o ?g. }

• W2961756674 endingPage "5015" @default.
• W2961756674 startingPage "5009" @default.
• W2961756674 abstract "The incidence of invasive meningitis disease (IMD) is increasing in Australia. A conjugate vaccine of meningococcal polysaccharide serogroups A, C, W and Y (MenACWY) is currently indicated for infants aged 12 months on the Australian National Immunisation Program. This study sought to determine the cost-effectiveness of a broader MenACWY vaccination program for Australians aged 15 to 19 years. A Markov model was constructed to simulate the incidence and consequences of IMD in Australians aged 0–84 years, with follow up until age 85 years. The model comprised four health states: ‘Alive with no previous IMD’, ‘Alive, post IMD without long-term complications’, ‘Alive, post IMD with long-term complications’ and ‘Dead’. Decision analysis compared the clinical consequences and costs of a vaccination program versus no vaccination from the perspective of the Australian health care system. Age-specific incidence of IMD and fatality rates were derived from Australian surveillance data. Vaccine coverage, vaccine efficacy and herd immunity were based on published data. The total cost for MenACWY vaccination was AU$56 per dose. Costs and health outcomes were discounted by 5% per annum (in the base-case analysis). Compared to no vaccination, a MenACWY vaccination program targeted at Australians aged 15–19 years was expected to prevent 1664 IMD cases in the Australian population aged 0–84 years followed up until age 85 years. The program would lead to 1131 life years (LYs) and 2058 quality adjusted life years (QALYs) gained at a total cost of AU$115 million (all discounted values). These equated to incremental cost-effectiveness ratios of AU$101,649 per LY gained and AU$55,857 per QALY gained. A probabilistic sensitivity analysis demonstrated a likelihood of cost-effectiveness of 34.6%, assuming a willingness to pay threshold of AU$50,000 per QALY gained. The likelihood of this program being cost-effective under a willingness to pay threshold AU$50,000 per QALY gained is 35%." @default.
• W2961756674 created "2019-07-23" @default.
• W2961756674 creator A5001215167 @default.
• W2961756674 creator A5033015551 @default.
• W2961756674 creator A5069137747 @default.
• W2961756674 creator A5078028015 @default.
• W2961756674 creator A5082008789 @default.
• W2961756674 date "2019-08-01" @default.
• W2961756674 modified "2023-09-27" @default.
• W2961756674 title "Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents" @default.
• W2961756674 cites W1965328620 @default.
• W2961756674 cites W1968354061 @default.
• W2961756674 cites W1970554001 @default.
• W2961756674 cites W1976058654 @default.
• W2961756674 cites W1978911041 @default.
• W2961756674 cites W1980424473 @default.
• W2961756674 cites W1983276032 @default.
• W2961756674 cites W1987029428 @default.
• W2961756674 cites W1989485865 @default.
• W2961756674 cites W2011534020 @default.
• W2961756674 cites W2018560622 @default.
• W2961756674 cites W2024393408 @default.
• W2961756674 cites W2025502898 @default.
• W2961756674 cites W2042284658 @default.
• W2961756674 cites W2047639252 @default.
• W2961756674 cites W2049579473 @default.
• W2961756674 cites W2057016943 @default.
• W2961756674 cites W2078039837 @default.
• W2961756674 cites W2082705433 @default.
• W2961756674 cites W2088622396 @default.
• W2961756674 cites W2095551099 @default.
• W2961756674 cites W2103334452 @default.
• W2961756674 cites W2103466062 @default.
• W2961756674 cites W2114244380 @default.
• W2961756674 cites W2115236824 @default.
• W2961756674 cites W2131220313 @default.
• W2961756674 cites W2132760372 @default.
• W2961756674 cites W2140925691 @default.
• W2961756674 cites W2168091352 @default.
• W2961756674 cites W2212244197 @default.
• W2961756674 cites W2313957548 @default.
• W2961756674 cites W2342242813 @default.
• W2961756674 cites W2728783735 @default.
• W2961756674 cites W2766206503 @default.
• W2961756674 cites W2783121961 @default.
• W2961756674 doi "https://doi.org/10.1016/j.vaccine.2019.07.008" @default.
• W2961756674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31301916" @default.
• W2961756674 hasPublicationYear "2019" @default.
• W2961756674 type Work @default.
• W2961756674 sameAs 2961756674 @default.
• W2961756674 citedByCount "8" @default.
• W2961756674 countsByYear W29617566742019 @default.
• W2961756674 countsByYear W29617566742020 @default.
• W2961756674 countsByYear W29617566742021 @default.
• W2961756674 countsByYear W29617566742023 @default.
• W2961756674 crossrefType "journal-article" @default.
• W2961756674 hasAuthorship W2961756674A5001215167 @default.
• W2961756674 hasAuthorship W2961756674A5033015551 @default.
• W2961756674 hasAuthorship W2961756674A5069137747 @default.
• W2961756674 hasAuthorship W2961756674A5078028015 @default.
• W2961756674 hasAuthorship W2961756674A5082008789 @default.
• W2961756674 hasConcept C106192422 @default.
• W2961756674 hasConcept C112930515 @default.
• W2961756674 hasConcept C120665830 @default.
• W2961756674 hasConcept C121332964 @default.
• W2961756674 hasConcept C144024400 @default.
• W2961756674 hasConcept C149923435 @default.
• W2961756674 hasConcept C187212893 @default.
• W2961756674 hasConcept C187316915 @default.
• W2961756674 hasConcept C203014093 @default.
• W2961756674 hasConcept C22070199 @default.
• W2961756674 hasConcept C2776645655 @default.
• W2961756674 hasConcept C2778458888 @default.
• W2961756674 hasConcept C2779583294 @default.
• W2961756674 hasConcept C2780454893 @default.
• W2961756674 hasConcept C2780801004 @default.
• W2961756674 hasConcept C2908647359 @default.
• W2961756674 hasConcept C3019080777 @default.
• W2961756674 hasConcept C523546767 @default.
• W2961756674 hasConcept C54355233 @default.
• W2961756674 hasConcept C61511704 @default.
• W2961756674 hasConcept C71924100 @default.
• W2961756674 hasConcept C86803240 @default.
• W2961756674 hasConcept C8891405 @default.
• W2961756674 hasConcept C99454951 @default.
• W2961756674 hasConceptScore W2961756674C106192422 @default.
• W2961756674 hasConceptScore W2961756674C112930515 @default.
• W2961756674 hasConceptScore W2961756674C120665830 @default.
• W2961756674 hasConceptScore W2961756674C121332964 @default.
• W2961756674 hasConceptScore W2961756674C144024400 @default.
• W2961756674 hasConceptScore W2961756674C149923435 @default.
• W2961756674 hasConceptScore W2961756674C187212893 @default.
• W2961756674 hasConceptScore W2961756674C187316915 @default.
• W2961756674 hasConceptScore W2961756674C203014093 @default.
• W2961756674 hasConceptScore W2961756674C22070199 @default.
• W2961756674 hasConceptScore W2961756674C2776645655 @default.
• W2961756674 hasConceptScore W2961756674C2778458888 @default.
• W2961756674 hasConceptScore W2961756674C2779583294 @default.

• next